681 related articles for article (PubMed ID: 31711453)
41. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
[TBL] [Abstract][Full Text] [Related]
42. Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.
Melchardt T; Troppan K; Weiss L; Hufnagl C; Neureiter D; Tränkenschuh W; Schlick K; Huemer F; Deutsch A; Neumeister P; Greil R; Pichler M; Egle A
J Natl Compr Canc Netw; 2015 Dec; 13(12):1501-8. PubMed ID: 26656519
[TBL] [Abstract][Full Text] [Related]
43. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
44. [Evaluation of GELTAMO-IPI for Patients with Diffuse Large B-cell Lymphoma].
Feng YX; Su LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):98-103. PubMed ID: 33554804
[TBL] [Abstract][Full Text] [Related]
45. Relationship between red cell distribution width and prognosis in patients with breast cancer after operation: a retrospective cohort study.
Yao D; Wang Z; Cai H; Li Y; Li B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31262969
[TBL] [Abstract][Full Text] [Related]
46. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B
Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134
[TBL] [Abstract][Full Text] [Related]
47. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
48. Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma.
Miao Y; Zhou XH; Guo JJ; Sun Q; Shi K; Wu JZ; Zhu HY; Wang L; Fan L; Xu W; Li JY
Cancer Med; 2019 Jun; 8(6):2751-2758. PubMed ID: 30980510
[TBL] [Abstract][Full Text] [Related]
49. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
50. Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma.
Shehata AMF; Aldesoky AI; Gohar SF
Hematology; 2019 Dec; 24(1):103-107. PubMed ID: 30198830
[TBL] [Abstract][Full Text] [Related]
51. Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma.
Wu S; Zhou Y; Hua HY; Zhang Y; Zhu WY; Wang ZQ; Li J; Gao HQ; Wu XH; Lu TX; Hua D
BMC Cancer; 2018 Oct; 18(1):997. PubMed ID: 30340560
[TBL] [Abstract][Full Text] [Related]
52. [The Prognostic Value of Prognostic Nutritional Index Combined with D-dimer in Patients with Diffuse Large B-Cell Lymphoma].
Han Y; Song Y; Wang Y; Jin QQ; Jiang HY; Chai Y; Zeng PY; Yue LL; Wu CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1385-1393. PubMed ID: 37846689
[TBL] [Abstract][Full Text] [Related]
53. [Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma].
Fu ZY; Zhu J; Song YQ; Liu WP; Ji XQ; Zhan SY
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Jun; 46(3):405-11. PubMed ID: 24943019
[TBL] [Abstract][Full Text] [Related]
54. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
55. Elevated red cell distribution width to platelet count ratio predicts poor prognosis in patients with breast cancer.
Takeuchi H; Abe M; Takumi Y; Hashimoto T; Miyawaki M; Okamoto T; Sugio K
Sci Rep; 2019 Feb; 9(1):3033. PubMed ID: 30816333
[TBL] [Abstract][Full Text] [Related]
56. Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients.
Jiang C; Teng Y; Zheng Z; Zhou Z; Xu J
Quant Imaging Med Surg; 2021 Jun; 11(6):2509-2520. PubMed ID: 34079720
[TBL] [Abstract][Full Text] [Related]
57. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer.
Koma Y; Onishi A; Matsuoka H; Oda N; Yokota N; Matsumoto Y; Koyama M; Okada N; Nakashima N; Masuya D; Yoshimatsu H; Suzuki Y
PLoS One; 2013; 8(11):e80240. PubMed ID: 24244659
[TBL] [Abstract][Full Text] [Related]
58. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
59. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
[TBL] [Abstract][Full Text] [Related]
60. Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients.
Shi Q; Shen R; Wang CF; Fan X; Qian Y; Ou-Yang BS; Zhao Y; Leboeuf C; Janin A; Cheng S; Wang L; Zhao WL
Mediators Inflamm; 2017; 2017():7960907. PubMed ID: 29109622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
